Product images are for illustrative purposes only and do not represent the availability of a specific peptide or medication.
The clinical safeguards gray-market peptides don't have
Available Today
Evergreen Lean is the currently open program. Individual therapies may also be available after clinical review.
A clinician-guided weight management program with GLP-1 treatment options when prescribed after an independent medical evaluation.
NAD+ and Glutathione are available individually when clinically appropriate. The Evergreen Recovery program is not currently open. BPC-157, TB-500, GHK-Cu, and the growth hormone secretagogues described below are not currently available through Evergreen; their regulatory status is under review.
EDUCATIONAL REFERENCE · NOT CURRENTLY AVAILABLE
In July 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six peptide-related bulk drug substances for potential inclusion on the 503A Bulks List. This recommendation is advisory only. It does not constitute FDA approval and does not make these peptides available for compounding. The FDA has not made a final determination. The peptides listed below are not currently available through Evergreen, and Evergreen has made no representation about whether or when that may change.
A synthetic peptide derived from a protein fragment found in gastric juice. It has been studied in preclinical research in connection with tissue and cellular signaling pathways. Its clinical use in humans has not been established and remains under scientific and regulatory review.
Regulatory status: PCAC-recommended for the 503A Bulks List (July 2026); FDA determination pending.
A synthetic fragment of thymosin beta-4, a protein involved in cellular processes. Research interest has centered on its role in biological signaling. Its clinical use remains under scientific and regulatory review.
Regulatory status: PCAC-recommended for the 503A Bulks List (July 2026); FDA determination pending.
A short tripeptide fragment of the alpha-MSH hormone. It has been explored in laboratory research related to inflammatory signaling pathways and remains under scientific and regulatory review.
Regulatory status: PCAC-recommended for the 503A Bulks List (July 2026); FDA determination pending.
A peptide encoded in mitochondrial DNA. It has been examined in laboratory research related to metabolic signaling pathways. Its clinical use remains under scientific and regulatory review.
Regulatory status: PCAC-recommended for the 503A Bulks List (July 2026); FDA determination pending.
A synthetic peptide based on a fragment of the ACTH hormone. It has been examined in research settings outside the United States. Its clinical use remains under scientific and regulatory review in the United States.
Regulatory status: PCAC-recommended for the 503A Bulks List (July 2026); FDA determination pending.
A synthetic tetrapeptide based on a peptide isolated from the pineal gland. It has been examined in laboratory research. Its clinical use remains under scientific and regulatory review.
Regulatory status: PCAC-recommended for the 503A Bulks List (July 2026); FDA determination pending.
A combination of the two substances described above. The combination has not been separately evaluated in the regulatory process.
Regulatory status: The individual substances were PCAC-recommended (July 2026); the combination was not separately reviewed. FDA determination pending.
A naturally occurring copper-binding tripeptide. It has been examined in laboratory research related to skin and tissue biology. Its clinical use remains under scientific and regulatory review.
Regulatory status: Not among the substances recommended by PCAC in July 2026; no FDA determination for 503A bulk compounding.
A synthetic analog of growth hormone-releasing hormone (GHRH). It has been examined in endocrine research.
Regulatory status: Not among the substances recommended by PCAC in July 2026; no FDA determination for 503A bulk compounding.
A combination of a GHRH analog and a growth hormone secretagogue peptide. It has been examined in endocrine research. Its clinical use remains under scientific and regulatory review, studied together in endocrine research settings.
Regulatory status: Not among the substances recommended by PCAC in July 2026; no FDA determination for 503A bulk compounding.
A synthetic growth hormone secretagogue peptide. It has been examined in endocrine research.
Regulatory status: Not among the substances recommended by PCAC in July 2026; no FDA determination for 503A bulk compounding.
A synthetic peptide derived from a fragment of the immune protein tuftsin. It has been examined in research settings outside the United States.
Regulatory status: Not among the substances recommended by PCAC in July 2026; no FDA determination for 503A bulk compounding.
A synthetic version of a naturally occurring thymic peptide. It has been examined in immune-system research. Its clinical use remains under scientific and regulatory review
Regulatory status: Not among the substances recommended by PCAC in July 2026; no FDA determination for 503A bulk compounding.
Regulatory note: A PCAC recommendation is not FDA approval and does not authorize a bulk drug substance for compounding. The FDA makes the final determination regarding inclusion on the 503A Bulks List. The substances listed above are not currently available through Evergreen.
Regulatory status last updated: September 2026
For Medications Currently Dispensed Through Evergreen
These standards apply only to medications currently dispensed through Evergreen’s licensed partner pharmacy network. They do not describe the peptides listed in the regulatory status section above.
Standards for sterile preparation followed for applicable medications currently dispensed through Evergreen
Patient-specific medications compounded by licensed partner pharmacies when permitted and prescribed
An independent evaluation by a licensed clinician determines whether an available treatment is appropriate
Compounded drugs are not reviewed or approved by FDA for safety, effectiveness, or quality.
Evergreen follows emerging peptide science and the evolving regulatory environment across recovery, metabolic health, healthy aging, and other areas of medicine.
This page summarizes the current regulatory status of certain peptides for reference. It is not a description of current or future Evergreen offerings.
Nothing listed in the regulatory status section of this page is currently available through Evergreen.
Guided by Experts
Dr. Casey Greene, PharmD, IFMCP, is one of a select few pharmacists in the country to hold A4M Peptide Therapy Certification. He leads Evergreen’s education program, translating current peptide science and regulatory developments into clear learning content.
Educational content does not establish that a peptide is available, appropriate for an individual, or eligible for compounding.
“Patients deserve clear information about regulatory status, licensed-clinician guidance, and pharmacy quality.”
We use cookies
We use cookies to analyze traffic and improve your experience. You can accept all or reject non-essential. Privacy